Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by ScienceFirston Mar 07, 2023 10:59am
254 Views
Post# 35323650

RE:It takes money to advance oncology R&D

RE:It takes money to advance oncology R&D

I have no official proof that a pp is in the making but yesterday's sudden drop had all the hallmarks of one.  If so, it's quite possible that they would have a base of new profile of investors (those that can move us higher).  They probably received interest from ASCO-GU, etc ...

At this point in time, with what's coming up, with now having reached the minimum threshold of data required by the FDA, priorizing the visibility on the US would make total sense.  And not having to rely on retail investors would be quite positive and would signal good things to come honestly for all of us.

We'll see.


____________

 

It takes money to advance oncology R&D

The pp only means that they need/want to advance milestones (Rutherrin, GBM, NSCLC, NML, additional CSS, etc ...) before NMIBC FDA decision is announced and my take is that Breakthrough designation has not yet been been submitted but that it will by end of Q1 as they alluded that they were awaiting on whether more patients (we had 6 more coming up in a very short timeframe after p#26) on potentially guidance from the FDA or have been waiting for urologists reports.  No matter what, they know where they're heading.  The next few months will confirm these advances.  

Remember that for GBM and NSCLC, we must hear about MSAB nominations.  That would be THE signal that we have KOL experts that back the potential of our ACT platform in these 2 complex and challenging indications that are worth B$$$.


<< Previous
Bullboard Posts
Next >>